![]() |
Name |
Acaciicolinol D
|
Molecular Formula | C15H24O3 | |
IUPAC Name* |
(2S,4S,6S)-9-(hydroxymethyl)-5,5-dimethyl-1-methylidenespiro[5.5]undec-9-ene-2,4-diol
|
|
SMILES |
CC1([C@H](C[C@@H](C(=C)[C@]12CCC(=CC2)CO)O)O)C
|
|
InChI |
InChI=1S/C15H24O3/c1-10-12(17)8-13(18)14(2,3)15(10)6-4-11(9-16)5-7-15/h4,12-13,16-18H,1,5-9H2,2-3H3/t12-,13-,15-/m0/s1
|
|
InChIKey |
KYEPXJWFBINNCW-YDHLFZDLSA-N
|
|
Synonyms |
Acaciicolinol D
|
|
CAS | NA | |
PubChem CID | 139590763 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 252.35 | ALogp: | 1.0 |
HBD: | 3 | HBA: | 3 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 60.7 | Aromatic Rings: | 2 |
Heavy Atoms: | 18 | QED Weighted: | 0.628 |
Caco-2 Permeability: | -4.643 | MDCK Permeability: | 0.00000766 |
Pgp-inhibitor: | 0 | Pgp-substrate: | 0.891 |
Human Intestinal Absorption (HIA): | 0.005 | 20% Bioavailability (F20%): | 0.992 |
30% Bioavailability (F30%): | 0.995 |
Blood-Brain-Barrier Penetration (BBB): | 0.12 | Plasma Protein Binding (PPB): | 29.43% |
Volume Distribution (VD): | 0.899 | Fu: | 78.88% |
CYP1A2-inhibitor: | 0.02 | CYP1A2-substrate: | 0.102 |
CYP2C19-inhibitor: | 0.012 | CYP2C19-substrate: | 0.711 |
CYP2C9-inhibitor: | 0.005 | CYP2C9-substrate: | 0.114 |
CYP2D6-inhibitor: | 0.002 | CYP2D6-substrate: | 0.084 |
CYP3A4-inhibitor: | 0.023 | CYP3A4-substrate: | 0.219 |
Clearance (CL): | 6.977 | Half-life (T1/2): | 0.49 |
hERG Blockers: | 0.022 | Human Hepatotoxicity (H-HT): | 0.341 |
Drug-inuced Liver Injury (DILI): | 0.071 | AMES Toxicity: | 0.032 |
Rat Oral Acute Toxicity: | 0.944 | Maximum Recommended Daily Dose: | 0.986 |
Skin Sensitization: | 0.464 | Carcinogencity: | 0.957 |
Eye Corrosion: | 0.06 | Eye Irritation: | 0.207 |
Respiratory Toxicity: | 0.987 |